688373 盟科药业
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-36.865-69.243-41.120-26.660-42.749
总资产报酬率 ROA (%)-17.099-43.686-31.593-20.532-34.349
投入资产回报率 ROIC (%)-19.678-49.074-33.692-21.557-37.106

边际利润分析
销售毛利率 (%)84.78582.80181.60881.69992.449
营业利润率 (%)-206.171-333.522-452.655-462.460-3,343.976
息税前利润/营业总收入 (%)-199.984-323.228-448.462-435.981-2,911.436
净利润/营业总收入 (%)-207.070-338.306-463.914-456.987-2,953.915

收益指标分析
经营活动净收益/利润总额(%)103.160103.870107.841121.401120.365
价值变动净收益/利润总额(%)-3.075-3.931-8.032-8.394-4.654
营业外收支净额/利润总额(%)0.3510.0051.024-1.200-13.224

偿债能力分析
流动比率 (X)2.6683.5267.71511.9065.410
速动比率 (X)2.4703.2777.44111.7165.293
资产负债率 (%)59.45548.30428.63018.90632.406
带息债务/全部投入资本 (%)42.89830.63213.1129.1547.511
股东权益/带息债务 (%)109.259193.434602.728918.363973.704
股东权益/负债合计 (%)68.195107.021249.282428.927208.583
利息保障倍数 (X)-28.926-31.344-50.535-20.766-69.367

营运能力分析
应收账款周转天数 (天)91.56174.41565.59546.74566.585
存货周转天数 (天)913.815726.712640.488671.2095,171.330